Evidence map›Paper›PMID 38994370›Full record

ArticleFrontiers in immunology2024

Mitophagy and clear cell renal cell carcinoma: insights from single-cell and spatial transcriptomics analysis.

Lai Jiang, Xing Ren, Jinyan Yang, Haiqing Chen, Shengke Zhang, Xuancheng Zhou, Jinbang Huang, Chenglu Jiang, Yuheng Gu, Jingyi Tang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lai Jiang *Clinical Medical College, Southwest Medical University, Luzhou, China.
Xing Ren *Department of Oncology, Chongqing General Hospital, Chongqing, China.
Jinyan Yang *School of Stomatology, Southwest Medical University, Luzhou, China.
Haiqing ChenClinical Medical College, Southwest Medical University, Luzhou, China.
Shengke ZhangClinical Medical College, Southwest Medical University, Luzhou, China.
Xuancheng ZhouClinical Medical College, Southwest Medical University, Luzhou, China.
Jinbang HuangClinical Medical College, Southwest Medical University, Luzhou, China.
Chenglu JiangClinical Medical College, Southwest Medical University, Luzhou, China.
Yuheng GuClinical Medical College, Southwest Medical University, Luzhou, China.
Jingyi TangClinical Medical College, Southwest Medical University, Luzhou, China.
Guanhu YangDepartment of Specialty Medicine, Ohio University, Athens, OH, United States.
Hao ChiClinical Medical College, Southwest Medical University, Luzhou, China.
Jianhua Qin *Department of Nephrology, Affiliated Hospital of Southwest Medical University, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clear Cell Renal Cell Carcinoma (ccRCC) is the most common type of kidney cancer, characterized by high heterogeneity and complexity. Recent studies have identified mitochondrial defects and autophagy as key players in the development of ccRCC. This study aims to delve into the changes in mitophagic activity within ccRCC and its impact on the tumor microenvironment, revealing its role in tumor cell metabolism, development, and survival strategies. Methods: Comprehensive analysis of ccRCC tumor tissues using single cell sequencing and spatial transcriptomics to reveal the role of mitophagy in ccRCC. Mitophagy was determined to be altered among renal clear cells by gene set scoring. Key mitophagy cell populations and key prognostic genes were identified using NMF analysis and survival analysis approaches. The role of UBB in ccRCC was also demonstrated by Results: Compared to normal kidney tissue, various cell types within ccRCC tumor tissues exhibited significantly increased levels of mitophagy, especially renal clear cells. Key genes associated with increased mitophagy levels, such as UBC, UBA52, TOMM7, UBB, MAP1LC3B, and CSNK2B, were identified, with their high expression closely linked to poor patient prognosis. Particularly, the ubiquitination process involving the UBB gene was found to be crucial for mitophagy and its quality control. Conclusion: This study highlights the central role of mitophagy and its regulatory factors in the development of ccRCC, revealing the significance of the UBB gene and its associated ubiquitination process in disease progression.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMitophagySingle-Cell AnalysisBiomarkers, TumorCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisTranscriptomeTumor MicroenvironmentBiomarkers, Tumorclear cell renal cell carcinomametabolic reprogrammingmitochondrial gene defectsmitophagymulti-omics analysisnon-negative matrix factorizationprognostic analysis

Identifiers

PMID38994370
PMCPMC11236570

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.